journal article·2025-09Open access

Cepharanthine Loaded TCPP‐MOF Triggers Pyroptosis Through TSPO Inhibition for Hepatocellular Carcinoma Sonodynamic‐Chemotherapy

Hai‐Tao Li, Jichu Zhao, Jing‐Yu Lu, Xing‐Chun Peng, Ning Han, Liu‐Gen Li, Nan‐Nan Chen, Yao‐Hua Lu, Li‐Jiong Wang, Fan Leng, Fei Zhu, Cunqing Kong, Jun Hu, Tong‐Fei Li

Advanced Healthcare Materials· Volume 14· Issue 23

Abstract

Abstract Pyroptosis is the critical approach for the induction of robust cancer cell death and activation of the immune microenvironment, which often results from mitochondrial damage. Herein, a combination strategy of sonodynamic‐chemotherapy is designed to achieve an anti‐heptocellular (HCC) effect, wherein the cepharanthine (Cep), a kind of functional phytomedicine, is loaded into the Tris(chlorisopropyl)Phosphate (TCPP) Metal–organic framework (MOF). The Cep@TCPP‐MOF is successfully developed, as characterized by techniques such as transmission electron microscopy (TEM) and dynamic light scattering (DLC). The tumor‐targeted ability of Cep@TCPP‐MOF is validated by in vivo imaging. In‐depth in vitro experiments presented Cep@TCPP‐MOF can be taken up by Huh‐7 and HepG2 cells, which collapse in response to the sonodynamic therapy (SDT). The released Cep can bind to an inactive translocator protein (TSPO), a kind of transporter on the membrane of mitochondria, while TCPP induces ROS generation under the SDT, thereby enhancing mitochondria damage. Further exploration shows that the Cep@TCPP‐MOF treatment induces pronounced pyroptosis, which leads to HCC inhibition. To sum up, sonodynamic‐chemotherapy nanoplatforms, composed by Cep‐loaded TCPP‐MOF are developed, which have sonodynamic responsiveness to release Cep and TCPP. TSPO inhibition‐induced mitochondrial damage by Cep, coupled with ROS generated by TCPP‐SDT, synergistically elicits pyroptosis and thereby fulfills the anti‐HCC role.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Metal-Organic Frameworks: Synthesis and Applications · Nanoplatforms for cancer theranostics · Heme Oxygenase-1 and Carbon Monoxide

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Shiyan Key Laboratory of Natural Medicine Nanoformulation Research Hubei Key Laboratory of Embryonic Stem Cell Research School of Basic Medical Sciences Hubei University of Medicine Renmin road No. 30 Shiyan Hubei 442000 P. R. China

Guizhou University of Traditional Chinese Medicine Shidong Road No. 50 Guiyang 550005 P. R. China

Center for Translational Medicine Suizhou Hospital Hubei University of Medicine Suizhou Hubei 441300 P. R. China

Department of Pathology Shenzhen Pingle Orthopedic Hospital (Shenzhen Pingshan Traditional Chinese Medicine Hospital) Guangzhou Province Shenzhen 518118 P. R. China

Funding

National Natural Science Foundation of China · Natural Science Foundation of Hubei Province · Natural Science Foundation of Shandong Province

References (42)

Show source-provided references
1. 10.3322/caac.2187110.3322/caac.21871 ↗
2. 10.1186/s12943-024-02101-z10.1186/s12943-024-02101-z ↗
3. 10.7150/thno.7108610.7150/thno.71086 ↗
4. 10.1038/s41401-022-00887-610.1038/s41401-022-00887-6 ↗
5. 10.1002/ptr.824210.1002/ptr.8242 ↗
6. 10.1002/adhm.20240468510.1002/adhm.202404685 ↗
7. 10.1002/adhm.20230156110.1002/adhm.202301561 ↗
8. 10.1002/adhm.20240074710.1002/adhm.202400747 ↗
9. 10.1002/smll.20230636410.1002/smll.202306364 ↗
10. 10.1021/acsbiomaterials.4c0034410.1021/acsbiomaterials.4c00344 ↗
11. 10.1002/adma.20240595310.1002/adma.202405953 ↗
12. 10.1039/C9CS00648F10.1039/C9CS00648F ↗
13. 10.1016/j.jconrel.2023.08.00310.1016/j.jconrel.2023.08.003 ↗
14. 10.1080/10717544.2022.212602710.1080/10717544.2022.2126027 ↗
15. 10.1016/j.actbio.2024.12.01010.1016/j.actbio.2024.12.010 ↗
16. 10.1016/j.canlet.2022.21559210.1016/j.canlet.2022.215592 ↗
17. 10.1002/adma.20240595310.1002/adma.202405953 ↗
18. 10.1007/s11060-021-03807-610.1007/s11060-021-03807-6 ↗
19. 10.1002/adhm.20210194610.1002/adhm.202101946 ↗
20. 10.1039/D3TB02562D10.1039/D3TB02562D ↗
21. 10.1186/s12951-024-02694-z10.1186/s12951-024-02694-z ↗
22. 10.1016/j.actbio.2024.01.04210.1016/j.actbio.2024.01.042 ↗
23. 10.1016/j.ijpharm.2022.12257210.1016/j.ijpharm.2022.122572 ↗
24. 10.1016/j.phymed.2024.15616210.1016/j.phymed.2024.156162 ↗
25. 10.1158/1538-7445.AM2017-10810.1158/1538-7445.AM2017-108 ↗
26. 10.1093/nar/gkx24710.1093/nar/gkx247 ↗
27. 10.1016/j.ejphar.2024.17683910.1016/j.ejphar.2024.176839 ↗
28. 10.3390/molecules2522544310.3390/molecules25225443 ↗
29. 10.1002/advs.20220666910.1002/advs.202206669 ↗
30. 10.1016/j.immuni.2023.10.00410.1016/j.immuni.2023.10.004 ↗
31. 10.3390/molecules2813501910.3390/molecules28135019 ↗
32. 10.1007/s43440-020-00132-z10.1007/s43440-020-00132-z ↗
33. 10.7883/yoken.66.2610.7883/yoken.66.26 ↗
34. 10.1186/s13020-019-0270-910.1186/s13020-019-0270-9 ↗
35. 10.62347/WDFF743210.62347/WDFF7432 ↗
36. 10.18433/J3ZP5F10.18433/J3ZP5F ↗
37. 10.1007/s12975-021-00979-110.1007/s12975-021-00979-1 ↗
38. 10.1186/s13046-024-03082-z10.1186/s13046-024-03082-z ↗
39. 10.1016/j.ijpharm.2025.12539610.1016/j.ijpharm.2025.125396 ↗
40. 10.1080/10717544.2021.200993610.1080/10717544.2021.2009936 ↗
41. 10.1016/j.ejps.2019.10504710.1016/j.ejps.2019.105047 ↗
42. 10.1002/ptr.824210.1002/ptr.8242 ↗